Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse

NCT00003775 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00003775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 1998
Completion date
May 31, 2006
Enrollment
60 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors